TABLE 3.
Treatment‐related adverse events.
| Adverse events, N (%) | Grade 1 (N = 39) | Grade 2 (N = 18) | Grade 3 (N = 18) |
|---|---|---|---|
| Hematological | |||
| Neutropenia | 3 (6.52%) | 0 (0.0%) | 0 (0.0%) |
| Lymphocytopenia | 7 (15.22%) | 0 (0.0%) | 2 (4.35%) |
| Leukopenia | 4 (8.70%) | 2 (4.35%) | 0 (0.0%) |
| Anemia | 4 (8.70%) | 7 (15.22%) | 0 (0.0%) |
| Metabolism and nutrition disorders | |||
| Hyponatremia | 4 (8.70%) | 0 (0.0%) | 0 (0.0%) |
| Hypokalemia | 4 (8.70%) | 0 (0.0%) | 1 (2.17%) |
| Decreased appetite | 3 (6.52%) | 0 (0.0%) | 0 (0.0%) |
| Gastrointestinal | |||
| Constipation | 3 (6.52%) | 0 (0.0%) | 0 (0.0%) |
| Vomiting | 6 (13.04%) | 0 (0.0%) | 1 (2.17%) |
| Nausea | 4 (8.70%) | 2 (4.35%) | 0 (0.0%) |
| Diarrhea | 16 (34.78%) | 11 (23.91%) | 12 (26.09%) |
| Abdominal pain | 6 (13.04%) | 0 (0.0%) | 0 (0.0%) |
| Abdominal distension | 0 (0.0%) | 0 (0.0%) | 1 (2.17%) |
| Other | |||
| Oral mucositis | 4 (8.70%) | 0 (0.0%) | 0 (0.0%) |
| Cough | 2 (4.35%) | 0 (0.0%) | 0 (0.0%) |
| Hand‐foot syndrome | 9 (19.57%) | 2 (4.35%) | 0 (0.0%) |
| Hot flashes | 2 (4.35%) | 0 (0.0%) | 0 (0.0%) |
| Fatigue | 8 (17.39%) | 0 (0.0%) | 0 (0.0%) |
| Rash | 6 (13.04%) | 1 (2.17%) | 1 (2.17%) |
| Skin ulcer | 0 (0.0%) | 0 (0.0%) | 1 (2.17%) |
| Elevated creatinine | 8 (17.39%) | 2 (4.35%) | 0 (0.0%) |
| Elevated ALT | 1 (2.17%) | 1 (2.17%) | 0 (0.0%) |
| Elevated AST | 5 (10.87%) | 0 (0.0%) | 1 (2.17%) |
| Dizziness | 3 (6.52%) | 0 (0.0%) | 0 (0.0%) |
| Headache | 3 (6.52%) | 0 (0.0%) | 0 (0.0%) |
| Myalgia | 1 (2.17%) | 0 (0.0%) | 0 (0.0%) |
| Arthralgia | 4 (8.70%) | 0 (0.0%) | 0 (0.0%) |
| Bone pain | 1 (2.17%) | 0 (0.0%) | 0 (0.0%) |
| Other | 10 (21.74%) | 0 (0.0%) | 0 (0.0%) |
Abbreviations: ALT, Alanine aminotransferase; AST, Aspartate aminotransferase.